We own the CMV vaccine franchise. CMV is a herpes family, which is a problem in both transplant patients and females of child-bearing age. We just did a deal with Astellas, which is a major Japanese company, which is a key player in the transplant market. I will tell you more about that.
The second target in the herpes family is Herpes Simplex 2. This is a major problem. It’s a sexually transmitted disease that leads to general lesions. The only antivirals available, we had some very exciting preclinical data in the therapeutic vaccine setting. But these are pipeline programs. We have key validating partnerships with some big pharmaceutical companies. We are one of the few companies by the way which has a GMP manufacturing facility where we have capacity to launch both our CMV and Allovectin programs worldwide. And finally, we have a strong balance sheet. In our recent guidance, we will end the year with about mid-50s million dollars in cash.
So, again a quick summary of our product pipeline. Allovectin-7 lead program in melanoma, market commercial opportunity is greater than $0.5 billion. The Phase 3 is fully enrolled, the top line data will be in the middle of the year. TransVax, again our product in lead transplant setting, our Phase 2 is completed. We expect to start a Phase 3 and a cease of Phase 2 trials in the solid organ transplant setting in the first half of next year.
Collategene is our program for treatment of peripheral arterial disease of the legs to a Japanese company, AnGes, which is for treatment of blockage of arteries where you inject an angiogenic growth factor. We expect that Phase 3 to be started sometime in 2012, early 2012. Now, CyMVectin is a big opportunity. This is for treatment of prevention of CMV infection of females of child-bearing age. The market is the size of Gardasil. And we have an IND allowed there. So, that’s a very exciting program for us for future product opportunity. I had mentioned the HSV-2 program and product extension applications for Allovectin-7.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV